Our Companies
Changing the World at the Molecular Level
Abridge
A patient's healthcare story is siloed, disjointed and inaccessible. Abridge started as a collaboration between the University of Pittsburgh Medical Center (UPMC) and Carnegie Mellon University (CMU) to build speech, voice, and language technologies to better capture our healthcare stories and empower the patient and unburden practitioners.
Patch'd
Patch’d is on a mission to prevent sepsis. Unlike other sepsis companies which focus on the inpatient setting (where only 20% of sepsis cases start/occur), Patch’d powers a simple wearable device with advanced computation to predict sepsis in the outpatient setting.
Dyno Therapeutics
Dyno Therapeutics creates novel adeno-associated virus (AAV) vectors that enable safe, efficient and targeted in vivo delivery for revolutionary new gene therapies. Dyno is systematically mapping the relationship between capsid sequence and function and optimizing AAV for improved therapeutic efficacy.
Revel
Using synthetic biology to design and manufacture superior ingredients, starting with coffee.
March Bio
March Biosciences is pioneering next-generation CAR-T cell therapies for T-cell cancers, solving a key technical challenge that has historically prevented effective treatment of these aggressive blood cancers while demonstrating promising early clinical results in patients with limited therapeutic options.
Reflex
Building next-generation Silent Speech Interfaces (SSI) to unlock a new frontier in hands-free, real-time communication
Preload Therapeutics
KdT build reprogramming cardiometabolic disease